1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
April 2020 in “Dermatology and therapy”
June 2017 in “Journal of The American Academy of Dermatology” The new treatment was safe and may effectively treat male pattern hair loss.
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
1 citations
,
June 2019 in “Journal of Cutaneous Immunology and Allergy” Squaric acid dibutylester can cause severe skin reactions in people with allergies.
January 2018 in “Journal of analytical, bioanalytical and separation techniques”
March 2006 in “Hair transplant forum international” The document's conclusion cannot be provided because the document cannot be parsed.
October 2021 in “Journal of Investigative Dermatology” COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
25 citations
,
July 2019 in “Journal of drug delivery science and technology” Researchers created better skin-application menthol capsules that are stable, safe, and penetrate the skin quickly.
13 citations
,
September 2013 in “Steroids” The DHT immunoassay is unreliable due to high cross-reactivity with testosterone.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
1 citations
,
June 2018 in “Dermatologic Surgery” 5 citations
,
January 2000 in “Inhalation Toxicology” Aqueous dispersion resin is safe to inhale at levels below 30 mg/m³.
April 2021 in “Journal of Investigative Dermatology” The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
July 2020 in “Pharmaceutical Research”
68 citations
,
March 2008 in “Experimental dermatology” The new assay can track and measure melanosome transfer between skin cells, confirming filopodia's role in this process.
July 2024 in “Journal of Investigative Dermatology” USPlus®Derm may help hair growth and maintain stem cells in male pattern hair loss.
2 citations
,
September 2011 in “Revista de Ciências Farmacêuticas Básica e Aplicada” The chili pepper shampoo was safe and well-liked by volunteers.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
8 citations
,
October 2023 in “JMIR dermatology” ChatGPT can be a helpful dermatology resource but should not replace professional consultations.
3 citations
,
February 2023 in “Journal of Investigative Dermatology” Ch55 may help reduce skin scarring and fibrosis.
April 2016 in “Journal of Investigative Dermatology” Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
1 citations
,
January 2002 in “Journal of Clinical Dermatology” The document's conclusion cannot be provided because the document is not accessible or understandable.
1 citations
,
January 2015 in “Research Journal of Pharmacy and Technology” The document's conclusion cannot be provided because the document is not accessible or understandable.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
May 2017 in “Journal of The American Academy of Dermatology” The treatment increased hair follicle counts and is potentially effective for male hair loss without serious side effects.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
6 citations
,
April 2021 in “Patient Preference and Adherence” Patients with non-small-cell lung cancer need significant survival gains to accept severe side effects.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.